NCT06057467 (ASAP) is a NA clinical trial of Anticoagulation Agents in Acute Ischemic Stroke, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT06057467?

NCT06057467 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT06057467?

Interventions in NCT06057467: Anticoagulation Agents.

What condition does NCT06057467 study?

NCT06057467 studies Acute Ischemic Stroke, Atrial Fibrillation.

Is NCT06057467 still recruiting?

NCT06057467 is currently status unknown. Last updated 18 March 2024.

Last reviewed 2024-03-18 · How we verify

NCT06057467: ASAP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Early Versus Late Initiation of Anticoagulation in Mild-to-moderate AIS Patients With NVAF

Status unknown NA Last updated 18 March 2024

What this trial tests

NA trial testing Anticoagulation Agents in Acute Ischemic Stroke in 2,351 participants. Status unknown.

Timeline

15 September 2023

Primary endpoint
1 October 2025

1 January 2026

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	2,351
Start date	15 September 2023
Primary completion	1 October 2025
Estimated completion	1 January 2026
Sites	2 locations across China

Drugs / interventions tested

Anticoagulation Agents — full drug profile →

Conditions studied

Acute Ischemic Stroke — all drugs for Acute Ischemic Stroke →
Atrial Fibrillation — all drugs for Atrial Fibrillation →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

18 and older, any sex, with Acute Ischemic Stroke or Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to compare the effectiveness between early and late initiation of anticoagulation therapy in acute ischemic stroke (AIS) patients with non-valvular atrial fibrillation (NVAF). Participants will be 1:1 randomized into early or late initiation group. The primary endpoint is early neurological deterioration (END) before discharge.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Optimal timing of oral anticoagulation initiation in patients with acute ischaemic stroke and atrial fibrillation: a comprehensive meta-analysis and systematic review.
Dilli Babu A, Singh S, Gorantla A, Ali Baig MF, et al · · 2024 · cited 5× · PMID 39608862 · DOI 10.1136/openhrt-2024-003002

Verify or expand the search:

Other trials of Anticoagulation Agents

Trials testing the same drug.

NCT07352358 — Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis · Phase 4 · recruiting
NCT06045858 — Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a · Phase 3 · not yet recruiting
NCT04527666 — Anticoagulation in Gastroesophageal Varices and JAK2 Mutation · unknown
NCT03761173 — FlowTriever All-Comer Registry for Patient Safety and Hemodynamics · completed

Other recruiting trials for Acute Ischemic Stroke

Currently open trials in the same condition.

NCT07115940 — Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours · NA · recruiting
NCT07404852 — Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemi · NA · recruiting
NCT07361302 — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Pe · Phase 3 · recruiting
NCT07436156 — SUMMIT RISE Study of Acute Ischemic Stroke Patients · Phase 4 · recruiting
NCT07203625 — Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours · Phase 4 · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06057467 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 18 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06057467.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing